AlzeCure Pharma announced a recent out-licensing agreement and ongoing collaboration with QuantumCell for NeuroRestore® (ACD856), a drug candidate in clinical development designed to enhance cognitive function and support brain signaling pathways.
Published
Signal category
Products & Services
Quote
“NeuroRestore® (ACD856) A drug candidate in clinical development designed to enhance cognitive function and support brain signaling pathways. We are especially proud of recent out-licensing agreement and the ongoing collaboration with QuantumCell around this promising program.”
— AlzeCure Pharma team
Company
AlzeCure Pharma
Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more
- Industry
- Biotechnology Research
- Location
- Stockholm, SE
- Company size
- 15 employees
AlzeCure Pharma is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease and pain. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has a project in the field of pain in the early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se.
Founded 2016